INCY Earnings Prediction
The chart below shows how INCY performed 10 days before and after its earnings report, based on data from the past quarters. Typically, INCY sees a +0.31% change in stock price 10 days leading up to the earnings, and a +0.38% change 10 days following the report. On the earnings day itself, the stock moves by -0.93%. This data can give you a slight idea of what to expect for the next quarter's release.
INCY Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
1.18B
16.32%
3.59%
Gross Margin
92.49%
-0.68%
0.05%
Operating Margin
25.24%
24.64%
69.40%
Net Margin
17.07%
-13.96%
82.37%
EPS
0.97
8.99%
79.63%
No Data Available
INCY Earnings Analysis
Incyte Corp Corporation (INCY.O) Earnings Conference Call
Positive
Revenue Growth Achievement: 2024 total revenues grew 15% to reach $4.2 billion, continuing steady growth since 2020.
Jakafi Sales Growth: Jakafi net sales were $2.8 billion, growing 8% year-over-year, with growth across all indications.
Opzelura Revenue Surge: Opzelura revenue grew 50% to $508 million, driven by new patients and refills in the US and expanding reimbursement outside the US.
Share Repurchase and Cash Reserves: Completed a $2 billion share repurchase in 2024 while maintaining a strong balance sheet with $2.2 billion in cash and no debt.
Future Revenue Diversification: Anticipated product launches and approvals expected to generate $1 billion in incremental revenues by 2029, diversifying revenue streams.
Negative
Net Revenue Growth Slowdown: Jakafi's net product revenue growth for 2024 was only 8%, a significant slowdown compared to previous years, indicating potential market saturation or increased competition.
Cost Management Concerns: Operating expenses increased by 10% year-over-year, outpacing revenue growth of 15%, which raises concerns about cost management and operational efficiency.
R&D Expense Increase: R&D expenses for the full year 2024 rose by 14%, reflecting a continued high investment in late-stage programs without immediate returns, potentially straining future profitability.
Projected Revenue Decline: The anticipated net product revenue for Jakafi in 2025 is projected to be lower than previously expected due to IRA-imposed price increase caps and increased 340B volumes, indicating pricing pressures ahead.
Q1 Revenue Decline Outlook: Opzelura's Q1 2025 net product revenue is expected to decline compared to Q4 2024, reflecting typical seasonal dynamics and potential challenges in maintaining growth momentum.
INCY FAQs
How does INCY typically perform around its earnings report dates?
Is Incyte Corp (INCY) Q4 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
INCY Earning Call Sentiment
Incyte Corporation (NASDAQ:INCY) Q4 2024 Earnings Call Transcript
INCY.O
-2.88%Positive
The earnings call summary indicates strong financial performance with increased revenues, a solid cash position, and significant share repurchases. The guidance has been raised, showing confidence in future growth. Despite some concerns in the Q&A about clinical trial specifics, overall sentiment is positive with plans for new product launches and market expansion. The market is likely to react positively to the raised guidance and strong financial health.
